Dyclonine
Based on 1 publication(s) in Google Scholar
Dyclonine (Dyclocaine) is an orally active, blood-brain barrier-permeable piperidine phenylacetone small molecule commonly used as a local anesthetic. Dyclonine acts as a highly selective allosteric antagonist of TRPV3; it also reversibly inhibits G9a, ALDH2 and ALDH3A1, non-competitively blocks AChE. Dyclonine activates the Nrf2/ARE pathway, relieves the epigenetic silencing of FXN, blocks Aβ42 aggregation, and promotes remyelination and reparative polarization of microglia. Dyclonine alleviates pruritus via TRPV3 inhibition; it is used in studies of neurodegenerative disease models based on its AChE inhibitory, antioxidant and remyelinating effects; it sensitizes drug-resistant tumors through ALDH inhibition, and combined use with protease inhibitors induces more tumor cell apoptosis; it inhibits Candida albicans in vitro. Dyclonine can be used for research on multiple diseases including neurodegenerative diseases, cancer and pruritic dermatitis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 586-60-7
- 分子式: C18H27NO2
- 分子量:289.41
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
MedChemExpress(MCE)の使用を引用している文献 Dyclonine
More
生物活性
製品説明
IC50 & Target
[1]|
TRPV3 |
ALDH2 |
ALDH3A1 |
AChE |
体外実験
Dyclonine selectively inhibits purified TRPV3 channels with an IC50 of 3.2 μM; it inhibits purified ALDH2 with an IC50 of 35 μM; it also inhibits purified ALDH3A1 with an IC50 of 76 μM; and it potently and selectively inhibits purified AchE in a non-competitive manner with an IC50 of 0.18 μM[1].
Dyclonine inhibits the proliferation of cultured cardiomyocytes at concentrations of 1-10 μM by suppressing ALDH2; it also inhibits the proliferation of HSC4 oral squamous cell carcinoma cells cultured in vitro, and restores the sensitivity of drug-resistant HSC4 cells to Sulfasalazine (HY-14655) via ALDH inhibition[1].
Dyclonine (0.3-10 μM; 48 h) dose-dependently increases the FXN protein level in lymphoblasts derived from Friedreich's ataxia (FA)[2].
Dyclonine (3-30 μM; 24 h) dose-dependently increases the level of FXN transcripts in lymphoblasts derived from Friedreich's ataxia (FA) patients, reaching a maximum induction of approximately 3.2-fold after treatment with 30 μM for 24 h, and exhibits a stronger inductive effect in cells with longer GAA repeat sequences[2].
Dyclonine (5 μM; 24 h) enhances the binding of Nrf2 to the conserved ARE site in the FXN locus in lymphoblasts from FA patients[2].
Dyclonine (1-10 μM) dose-dependently inhibits the activity of histone methyltransferase G9a in nuclear extracts of healthy lymphoblasts; it also rescues the aconitase activity defect in lymphoblasts derived from Fanconi anemia (FA)[2].
Dyclonine (3-30 μM; with 1 mM 2-APB (HY-W009724)) modulates the inhibitory potency against mouse TRPV3 channels overexpressed in HEK 293T cells, and this regulatory effect relies on amino acid residues located in the channel pore region. Relative to wild-type TRPV3 with an IC50 value of 3.2 μM, L630W, N643A, I644W and L655A mutations reduce its inhibitory capacity, whereas L642A and I659A mutations strengthen its channel-blocking activity[3].
Dyclonine (15 μM) enhances the cytotoxic effect of 40 nM Bortezomib (HY-10227), reduces the survival rate of drug-resistant RPMI8226.BR multiple myeloma cells by approximately 80%, and induces cell apoptosis; it also enhances the cytotoxic activity of MG132 (HY-13259), inhibits the proliferation of BT549 and MDA-MB-231 breast cancer cells, and induces their apoptosis[1].
Dyclonine inhibits the growth of Saccharomyces cerevisiae in vitro, and exerts a synergistic effect with Calyculin A (HY-18983) to enhance this effect by targeting sterol biosynthetic enzymes including Erg2p and ERG24[1].
Dyclonine increases mitochondrial ATP production in cultured primary neurons and enhances their spontaneous excitatory postsynaptic current activity; it also inhibits the formation of Aβ42 oligomers in vitro[1].
Dyclonine potently protects fibroblasts derived from Fanconi anemia (FA) from diamide-induced oxidative stress, with an EC50 of approximately 0.2 μM[2].
Dyclonine (1.25-10 μM; 24 h) dose-dependently activates the Nrf2/ARE pathway in stable HeLa-ARE-luciferase cells, and luciferase activity is induced to approximately 2.5-fold after treatment with 10 μM for 24 h[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:FA patient lymphoblasts
-
Concentration:0.3, 1, 3, 5, 10 μM
-
Incubation Time:48 h
-
Result:Dose-dependently increased FXN protein levels relative to vehicle-treated controls.
-
Cell Line:FA patient lymphoblasts
-
Concentration:3, 5, 10, 15, 30 μM
-
Incubation Time:24 h
-
Result:Dose-dependently increased FXN transcript levels relative to vehicle-treated controls.
Showed induction magnitude correlated with GAA repeat length in FXN alleles, with longer repeats showing greater transcript induction.
体内実験
Dyclonine facilitates oligodendrogenesis, remyelination and the conversion of regenerative microglia upon oral delivery in mouse models with drug-triggered brain demyelination lesions[1].
Dyclonine (1-50 μM; intradermal injection; single administration) dose-dependently ameliorates TRPV3-mediated acute pruritus in mice, with the highest tested dose (50 μM) reducing the number of carvacrol (HY-N0711)-induced scratching bouts to 18.0 within 30 min[3].
Dyclonine reduces the number and proliferative activity of cardiomyocytes in neonatal mice after 14 days of treatment; it enhances the tumor volume reduction efficacy of Sulfasalazine in a mouse model of chemoresistant head and neck squamous cell carcinoma; and it improves the substrate oxidation capacity of whole-brain mitochondria in mice[1].
Dyclonine (1-10 mg/kg; intraperitoneal injection, oral administration; daily dosing; for 1 week) dose-dependently increases the levels of frataxin protein and Nrf2 target proteins, as well as aconitase activity, in the cerebellum of FA-YG8 mice[2].
Dyclonine (25 mg/kg; p.o.; daily; 4 weeks) restores the activity of succinate dehydrogenase in the liver, prevents the decline in balance beam performance, and increases the frataxin protein level by up to 2-fold in FA-PandKIKO mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J, FA-YG8 hemizygous (hFXN+/- with FXN (GAA)190 expansion; mFxn-/-)[2]
-
Dosage:1, 3 mg/kg (i.p.)
1, 3, 5, 10 mg/kg (p.o.) -
Administration:i.p.; daily; 1 week
p.o.; daily; 1 week -
Result:Elevated frataxin protein abundance (normalized to β-actin) in mouse cerebellar lysates after intraperitoneal and oral administration.
Boosted cerebellar aconitase activity to a dF/dt value of ~70 at 5 mg/kg oral dosage versus ~45 in vehicle-treated counterparts.
Upregulated Nrf2 downstream proteins HO1, NQO1 and GPX4 (normalized to β-actin) in a dose-dependent manner after oral treatment, with maximal 2.9-fold HO1, 2.2-fold NQO1 and 1.7-fold induction of GPX4 at 10 mg/kg.
-
Animal Model:C57BL/6J, FA-PandKIKO (mFxn+/- with FXN (GAA)230 expansion; mFxn-/-)[2]
-
Dosage:25 mg/kg
-
Administration:p.o.; daily; 4 weeks
-
Result:Elevated hepatic succinate dehydrogenase activity to a dF/dt value of ~0.04 within 25-30 min versus ~0.04 in vehicle groups.
Blocked progressive decline of level beam traversal speed and produced notable behavioral improvement relative to vehicle-treated mice.
Upregulated cerebellar frataxin protein by ~1.5-fold after one-week administration and up to ~2-fold following four-week continuous dosing, normalized to β-actin.
-
Animal Model:C57BL/6J (6- to 8-week-old, WT and TRPV3-/-)[3]
-
Dosage:1, 10, 50 μM
-
Administration:i.d.; single dose
-
Result:Suppressed carvacrol-triggered scratching episodes in wild-type mice in a concentration-dependent manner.
化学情報
-
CAS 番号 586-60-7
-
分子量 289.41
-
分子式 C18H27NO2
-
SMILES
O=C(CCN1CCCCC1)C2=CC=C(C=C2)OCCCC
-
別名
Dyclocaine
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Elife
Therapeutic inhibition of keratinocyte TRPV3 sensory channel by local anesthetic dyclonine. [Abstract]2021 Apr 20:10:e68128. PMID: 33876725
プロトコル
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
TPA/Croton Oil Ear Edema and Dermatitis
The TPA (12-O-tetradecanoylphorbol-13-acetate) and croton oil-induced mouse ear edema model is a well-established acute cutaneous inflammation system used to evaluate topical anti-inflammatory activity by measuring edema formation, neutrophil infiltration, vascular permeability, and cytokine-mediated skin responses in vivo. The inflammatory response is triggered by topical application of phorbol esters (TPA) or croton oil constituents, leading to rapid activation of protein kinase C signaling, leukocyte recruitment, and increased vascular permeability, which can be quantified by ear thickness, weight, dye extravasation, and biochemical markers such as myeloperoxidase (MPO) activity and pro-inflammatory mediators in ear tissue homogenates. This model is widely used for screening anti-inflammatory agents, where reductions in edema and inflammatory biomarkers reflect suppression of acute dermal inflammation and immune cell infiltration. Histological evaluation typically confirms epidermal
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
純度とドキュメンテーション
参考文献
[1]. Bailly C, et al. A new horizon for the anesthetic drug dyclonine. Biochemical pharmacology. 2026 Feb;244:117569. [Content Brief]
[2]. Sahdeo S, et al. Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's ataxia. Human molecular genetics. 2014 Dec 20;23(25):6848-62. [Content Brief]
[3]. Liu Q, et al. Therapeutic inhibition of keratinocyte TRPV3 sensory channel by local anesthetic dyclonine. eLife. 2021 Apr 20;10:e68128. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)